Gigagen Inc., of South San Francisco, launched its Surge Discovery service at the BIO 2017 International Conference in San Diego. The company said the antibody discovery and engineering service can deliver fully characterized monoclonal antibodies to pharmaceutical customer within six weeks, entirely replacing hybridoma and phage display.